The team at Roche’s Basel-based underdog R&D group pRED has something to cheer about today. The FDA has designated their autism drug RG7314 (balovaptan) as a “breakthrough” therapy worthy of VIP treatment at the agency.
{iframe}https://endpts.com/roche-scores-an-unusual-breakthrough-at-the-fda-for-an-autism-drug/{/iframe}